Rilonacept ( DrugBank: Rilonacept )


4 diseases
告示番号疾患名(ページ内リンク)臨床試験数
51全身性強皮症1
106クリオピリン関連周期熱症候群3
107若年性特発性関節炎2
266家族性地中海熱1

51. 全身性強皮症


臨床試験数 : 523 薬物数 : 608 - (DrugBank : 156) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 215
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01538719
(ClinicalTrials.gov)
December 201121/2/2012IL1-TRAP, Rilonacept, in Systemic SclerosisRandomized, Double-Blind, Placebo-Controlled Trial if IL1-TRAP, Rilonacept, in Systemic Sclerosis -A Phase I/II Biomarker TrialScleroderma;Systemic Sclerosis;Diffuse Scleroderma;Diffuse Systemic SclerosisDrug: Rilonacept;Other: PlaceboBoston UniversityRegeneron PharmaceuticalsCompleted18 YearsN/AAll24Phase 1/Phase 2United States

106. クリオピリン関連周期熱症候群


臨床試験数 : 42 薬物数 : 24 - (DrugBank : 4) / 標的遺伝子数 : 4 - 標的パスウェイ数 : 48
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01045772
(ClinicalTrials.gov)
January 20097/1/2010Safety and Tolerability of Rilonacept in Muckle-Wells Syndrome (MWS) or Schnitzler Syndrome (SchS)A Single-Centre, Open Label Study of the Safety and Tolerability of Rilonacept in Subjects Living in Germany With Muckle-Wells Syndrome (MWS), a Cryopyrin-Associated Periodic Syndrome (CAPS), or Schnitzler Syndrome (SchS)Muckle-Wells Syndrome;Schnitzler SyndromeDrug: rilonaceptCharite University, Berlin, GermanyNULLCompleted18 YearsN/ABoth10Phase 2Germany
2EUCTR2006-004290-97-DE
(EUCTR)
19/12/200817/10/2006A Single-Centre, Open Label Study of the Safety and Tolerability of Rilonacept in Subjects Living in Germany with Muckle-Wells Syndrome (MWS), a Cryopyrin-Associated Periodic Syndrome, or Schnitzler’s Syndrome (SchS). - ACCILTRA1A Single-Centre, Open Label Study of the Safety and Tolerability of Rilonacept in Subjects Living in Germany with Muckle-Wells Syndrome (MWS), a Cryopyrin-Associated Periodic Syndrome, or Schnitzler’s Syndrome (SchS). - ACCILTRA1 The medical condition to be investigated was first described by Muckle and Wells 1962. The Muckle-Wells syndrome (MWS) is rare and characterized by chronic recurrent urticaria, periodic arthritis, sensorineural deafness, general signs of inflammation and secondary amyloidosis. Schnitzler syndrome (SchS) is rare and characterized by chronic, nonpruritic urticaria and a monoclonal immunoglobulin M gammopathy. Symptoms are recurrent fever, bone pain, muscle pain, arthralgia or arthritis.Trade Name: RilonaceptCharité Universitätsmedizin Berlin, Department of Dermatology and AllergyNULLNot RecruitingFemale: yes
Male: yes
Germany
3NCT00288704
(ClinicalTrials.gov)
December 20056/2/2006Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)IL1T-AI-0505: A Multi-center, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, & Efficacy of Rilonacept in Subjects With Cryopyrin-Associated Periodic Syndromes (CAPS) Using Parallel Group & Randomized Withdrawal DesignsFamilial Cold Autoinflammatory Syndrome (FCAS);Familial Cold Urticaria;Muckle-Wells Syndrome (MWS);Genetic Diseases, InbornDrug: rilonacept 160 mg;Drug: PlaceboRegeneron PharmaceuticalsNULLCompleted7 YearsN/AAll104Phase 3United States

107. 若年性特発性関節炎


臨床試験数 : 441 薬物数 : 282 - (DrugBank : 56) / 標的遺伝子数 : 52 - 標的パスウェイ数 : 142
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00534495
(ClinicalTrials.gov)
November 200824/9/2007Safety and Effectiveness of Rilonacept for Treating Systemic Juvenile Idiopathic Arthritis in Children and Young AdultsRandomized Placebo Phase Study of Rilonacept in the Treatment of Systemic Juvenile Idiopathic Arthritis (RAPPORT)Juvenile Idiopathic ArthritisBiological: RilonaceptMontefiore Medical CenterNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Completed18 Months19 YearsAll71Phase 2United States
2NCT01803321
(ClinicalTrials.gov)
November 200528/2/2013Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA)A Pilot, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose, Safety, Tolerability and Preliminary Efficacy Study of Two Dose Levels of IL-1 Trap Administered Subcutaneously in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA)Systemic Juvenile Idiopathic ArthritisDrug: rilonacept (IL-1 Trap);Other: PlaceboRegeneron PharmaceuticalsNULLCompleted4 Years20 YearsBoth24Phase 1United States

266. 家族性地中海熱


臨床試験数 : 28 薬物数 : 24 - (DrugBank : 6) / 標的遺伝子数 : 14 - 標的パスウェイ数 : 59
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00582907
(ClinicalTrials.gov)
August 200819/12/2007Rilonacept for Treatment of Familial Mediterranean Fever (FMF)Phase 2 Study of IL-1 Trap (Rilonacept) for Treatment of Familial Mediterranean Fever (FMF)Familial Mediterranean FeverDrug: Rilonacept;Drug: PlaceboThe Cleveland ClinicNULLCompleted4 YearsN/AAll14Phase 2United States